BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 93 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,623 | -51.3% | 18,033 | +28.1% | 0.00% | – |
| Q2 2023 | $93,720 | +15114.3% | 14,072 | +42542.4% | 0.00% | – |
| Q1 2023 | $616 | -13.1% | 33 | 0.0% | 0.00% | – |
| Q4 2022 | $709 | -85.8% | 33 | -92.0% | 0.00% | – |
| Q3 2022 | $5,000 | -37.5% | 415 | -32.1% | 0.00% | – |
| Q2 2022 | $8,000 | -46.7% | 611 | -14.8% | 0.00% | – |
| Q1 2022 | $15,000 | -11.8% | 717 | -13.3% | 0.00% | – |
| Q4 2021 | $17,000 | -46.9% | 827 | -21.2% | 0.00% | – |
| Q3 2021 | $32,000 | -22.0% | 1,050 | -24.9% | 0.00% | – |
| Q2 2021 | $41,000 | -80.7% | 1,398 | -71.6% | 0.00% | – |
| Q1 2021 | $212,000 | -10.9% | 4,916 | -4.7% | 0.00% | -100.0% |
| Q4 2020 | $238,000 | +15.0% | 5,161 | +7.8% | 0.00% | 0.0% |
| Q3 2020 | $207,000 | +66.9% | 4,789 | +105.0% | 0.00% | – |
| Q2 2020 | $124,000 | +82.4% | 2,336 | -22.9% | 0.00% | – |
| Q1 2020 | $68,000 | – | 3,028 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |